Main Topics

Leukemia drug recognized by FDA as a breakthrough therapy

The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed / refractory FLT3-ITD acute myeloid leukemia ( AML ). This identification will accelerate the development of quizartinib and is...

FDA updates medication regimen for chronic lymphocytic leukemia

The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on...

The combination of two monoclonal antibodies for the treatment of lymphoma is 50% effective

According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe...

Chemotherapy and immunotherapy combinations for the treatment of leukemia

According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab ( nivolumab ) showed...

FDA approves first rituximab biosimilar to treat lymphoma

On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin’s lymphoma (NHL).  Rituximab is a monoclonal antibody against...

The first monotherapy for leukemia received FDA approval

The US FDA has approved gilteritinib ( Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or refractory acute myeloid leukemia ( AML ). When used with gilteritinib , it also awards...

Compared with chemotherapy and immunization, ibrutinib is more effective in treating elderly leukemia

The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are treated with a new targeted drug ibrutinib...

Combination therapy for the treatment of leukemia

Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed / refractory chronic lymphocytic leukemia ( CLL ), resulting in a high rate of undetectable minimal residual disease ( uMRD ),...

New regimen for patients with lymphoma prolongs PFS by up to 28 months

12 Yue 3 days, a study “The Lancet” published online, for CD30 -positive outer peripheral T -cell lymphoma patients, this rituximab, cyclophosphamide, doxorubicin and prednisone ( A + CHP ) Better than cyclophosphamide, doxorubicin,...

Be alert to early symptoms of leukemia and keep children away from threats

Leukemia In the clinical field of medicine, leukemia is also called blood cancer and belongs to the category of malignant tumors. It is mainly divided...

Lymphoma prevention requires attention to these symptoms

Lymphoma Many people think that their body resistance is high, and think that malignant tumors such as lymphoma are still far away from us. In...

Why do young people have a high incidence of lymphoma?

Lymph People have very little knowledge of lymph. The neck, groin, and armpits are all lymph. If there is a problem with the lymphatic system,...

Need help? Our team is ready to assist you.

We wish a speedy recovery for your loved ones.

Scan the code